15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study
The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-naïve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.
Authors
- Yongcheng Sun
- Ping Zhang (ORCID: https://orcid.org/0000-0002-4796-6529)
- Yu Wang (ORCID: https://orcid.org/0000-0003-1562-7562)
- Liping Mao
- Baodong YaoYujie YanXianwu Ye
- Guifang Ouyang (ORCID: https://orcid.org/0009-0007-7273-5742)
- Yinjun LOU
- BinBin Lai
- Lixia Sheng
- Chen Mei (ORCID: https://orcid.org/0000-0002-2390-0066)
- Hongyan Tong
- Jin Zhang
- De Zhou
- Lieguang Chen
- Huafeng Wang
- Wenyuan Mai
- Xiao Yan
- Wanzhuo Xie
- Huifang Jiang
- Shanhao Tang
- Liya Ma
- Wenjun Wu
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang Provincial Hospital of TCM (CN)
- Tongde Hospital of Zhejiang Province (CN)
- Hangzhou Hospital of Traditional Chinese Medicine (CN)
- Ningbo University Affiliated Hospital (CN)
- Ningbo First Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3390/cancers18010159
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00